申请人:Revolution Medicines, Inc.
公开号:US20160304548A1
公开(公告)日:2016-10-20
Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3′-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2′epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
披露了与AmB相比具有改善的治疗指数的Amphotericin B(AmB)衍生物。这些AmB衍生物包括根据公式(I)的C16脲、碳酸酯和酰胺;根据公式(II)的C3′-取代的C16脲、碳酸酯和酰胺;根据公式(III)的C16酰基;根据公式(IV)的C2′epi-C16脲、碳酸酯和酰胺;以及根据公式(V)的C16噁唑烷酮衍生物。还披露了包括这些AmB衍生物的药物组合物,以及使用这些AmB衍生物的治疗方法。